AroCell 관리

관리 기준 확인 0/4

AroCell CEO는 Anders Hultman, Jan2021 에 임명되었습니다 의 임기는 3.83 년입니다. 는 SEK 454.72K 가치에 해당하는 회사 주식의 0.49% 직접 소유합니다. 454.72K. 경영진과 이사회의 평균 재임 기간은 각각 1.3 년과 2.7 년입니다.

주요 정보

Anders Hultman

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3.8yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	1.3yrs
이사회 평균 재임 기간	2.7yrs

최근 관리 업데이트

Recent updates

CEO

Anders Hultman (50 yo)

3.8yrs

테뉴어

Mr. Anders Hultman, B.Sc., has been Chief Executive Officer at AroCell AB (publ) since January 11, 2021. He serves as Director at Polymer Factory Sweden AB since 2024. Mr. Hultman served as Chief Financial...

리더십 팀

이름	위치	테뉴어	보상	소유권
Anders Hultman	Chief Executive Officer	3.8yrs	데이터 없음	0.49% SEK 454.7k
Lars Jakobsson	Acting Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Jonas Söderholm	Global Medical Lead	no data	데이터 없음	데이터 없음
Gustav Sten	Chief Operating Officer	2.9yrs	데이터 없음	0.036% SEK 34.1k
Kiran Jagarlamudi	Chief Scientific Officer	1.8yrs	데이터 없음	0.0069% SEK 6.5k
Gunnar Wahlberg	Chief Sales Officer	less than a year	데이터 없음	0.065% SEK 60.9k
Marie Torstensson	Chief Marketing Officer	less than a year	데이터 없음	0.033% SEK 30.7k
Ellen Dittberner	Chief Finance Officer (Leave of Absence)	less than a year	데이터 없음	데이터 없음
Tina Yang	Chief Quality Officer	2.8yrs	데이터 없음	0.0033% SEK 3.1k

1.3yrs

평균 재임 기간

경험이 풍부한 관리: AROC 의 관리팀은 경험 (평균 재직 기간 1.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Fredrik Lindgren	Director	less than a year	데이터 없음	데이터 없음
Clas Runnberg	Independent Director	1.8yrs	SEK 91.00k	0.11% SEK 101.8k
Staffan Eriksson	Member of Advisory Board	3.7yrs	SEK 60.00k	데이터 없음
Max Pihlqvist	Chairman of the Board	2.8yrs	SEK 150.00k	12.49% SEK 11.7m
Eva Nordström	Independent Director	4.8yrs	SEK 150.00k	0.052% SEK 48.7k
Agneta Alm	Independent Director	2.5yrs	SEK 150.00k	0.0087% SEK 8.1k

2.7yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: AROC 의 이사회는 경험(평균 재직 기간 2.7 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

AroCell 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

AroCell AB (publ), Annual General Meeting, May 22, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Chief Executive Officer recently bought kr221k worth of stock

High number of new directors

Recent updates

New major risk - Market cap size

AroCell Announces New Study Published on the Prognostic Value of sTK1 in Prostate Cancer

Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.056 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.06 loss per share (vs kr0.067 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023)

AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024

AroCell AB (publ), Annual General Meeting, May 22, 2024

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

Now 22% undervalued after recent price drop

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)

AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

Consensus revenue estimates fall by 12%

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)

New major risk - Market cap size

AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer

New major risk - Market cap size

Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)

Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)

Price target decreased to kr2.30

High number of new and inexperienced directors

Consensus revenue estimates increase by 17%

Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)

AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument

High number of new and inexperienced directors

Chief Executive Officer recently bought kr221k worth of stock

AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market

First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)

Price target decreased to kr2.00

High number of new directors

AroCell AB (publ) Announces CFO Changes

Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)

High number of new directors

AroCell AB (publ), Annual General Meeting, May 24, 2022

Head of Operations recently bought kr81k worth of stock

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)

AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.

Chief Commercial Officer has left the company

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

New 90-day high: kr3.41

Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)

AroCell AB (publ), Annual General Meeting, May 06, 2021

Head of Operations recently bought kr91k worth of stock

Head of Operations recently bought kr91k worth of stock

AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical Officer

AroCell AB (publ) Appoints Anders Hultman as CEO

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

New 90-day low: kr2.43

Earnings released

New 90-day high - kr3.64

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령